On March 27, Lancôme—long recognized for pioneering a science-driven approach to skincare—announced the launch of its new skincare line, Absolue Longevity MD. The range is set to be unveiled at the American Academy of Dermatology Annual Meeting in Denver, Colorado, and is positioned as the brand’s most significant launch in the past two decades.
This new line represents a step beyond traditional “anti-aging” skincare, redefining the category through the concept of the skin’s “biological age.” By integrating scientific evidence, clinical research, and doctor-recognized ingredients, Lancôme brings the concept of longevity into the beauty space in a meaningful and structured way.
A Fusion with Cutting-Edge Biotechnology
At the core of this development is Lancôme’s collaboration with Swiss biotechnology company Timeline®. Its proprietary ingredient, Mitopure®, is based on Urolithin A and is widely recognized as a longevity-focused compound. This marks the first time it has been applied to skincare on a global scale.
In addition, through a partnership with Korea-based NanoEntek, Lancôme introduces a diagnostic technology called Cell BioPrint™. This system analyzes skin-surface biomarkers to assess the skin’s “visible biological age,” enabling more personalized and targeted skincare recommendations.
A Three-Stage “Intervention-Based” Skincare Approach
The range is structured around three distinct approaches tailored to different stages of skin aging:
- ANTICIPATE, designed to prevent early signs of aging
- INTERCEPT, aimed at addressing signs as they begin to appear
- RESET, developed to act on more visible and advanced changes
Each stage is supported by dedicated formulations, designed not merely to respond to changes, but to actively act on the underlying shifts occurring within the skin.
Bridging Medicine and Beauty: A New Advisory Body
Alongside the launch, Lancôme has established its first-ever Longevity MD Advisors Board, composed of medical experts. The board goes beyond traditional endorsement, aiming to expand the understanding of longevity from both medical and societal perspectives.
Vania Lacascade, Global Brand President of Lancôme, commented: “Lancôme’s presence at the AAD convention marks a defining step into a new era of skin longevity. By unveiling Absolue Longevity MD at the heart of the medical community, we are helping bridge the gap between cutting-edge science and women’s everyday lives. Lancôme is demonstrating its commitment to scientific rigor by validating the Longevity MD formulas with dermatologists and forming its first ever MD Advisory Board focused exclusively on longevity. Through this new Longevity MD advisors board we aim to democratize longevity science and empower every woman to take control of her skin-aging journey and embrace her vitality.”
The board includes Dr. David Luu, a cardiac surgeon and entrepreneur; Dr. Tiffany Moon, a board-certified anesthesiologist; Dr. Gabrielle Lyon, a specialist in nutritional science; and Dr. Amy Killen, an expert in regenerative medicine.
A New Approach Centered on Mitochondrial Function
A defining feature of the range is its focus on mitochondrial function—the energy source of skin cells. As this function declines with age, it contributes to visible signs of aging. By targeting this biological process, the formulations aim to support fundamental aspects such as skin firmness and renewal.
The combination of Timeline’s Mitopure® and Lancôme’s proprietary compounds is positioned as the brand’s most significant formulation breakthrough since the introduction of Pro-Xylane two decades ago.
From “Anti-Aging” to “Longevity”
The beauty industry is undergoing a broader shift—from the traditional approach of “correcting aging” to a longevity-driven mindset focused on maintaining health and vitality over time. Skincare is no longer limited to surface-level enhancement; it is evolving into a field that intersects with science and medicine, redefining the very concept of quality of life.
Copyright © 2026 Oui Speak Fashion. All rights reserved.